췌장 누공이라고 불리는 외과 적 합병증을 예방하기 위해 수술 전의 란렉 타이드 대 위약
수술 후 췌장 누공의 예방을위한 란 레오 티드의 무작위 III 상사 시험
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
PRIMARY OBJECTIVE:
I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.
SECONDARY OBJECTIVES:
I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.
II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.
ADDITIONAL OBJECTIVES:
I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.
II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.
BANKING OBJECTIVE:
I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Dana Sparks
- 전화번호: 210-614-8808
- 이메일: dsparks@swog.org
연구 연락처 백업
- 이름: Andrea Garcia
- 전화번호: 210-614-8808
- 이메일: agarcia@swog.org
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- 정지된
- University of Alabama at Birmingham Cancer Center
-
Daphne, Alabama, 미국, 36526
- 정지된
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, 미국, 36532
- 정지된
- Thomas Hospital
-
Mobile, Alabama, 미국, 36607
- 정지된
- Mobile Infirmary Medical Center
-
Saraland, Alabama, 미국, 36571
- 정지된
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Gilbert, Arizona, 미국, 85234
- 정지된
- Banner MD Anderson Cancer Center
-
-
California
-
Duarte, California, 미국, 91010
- 정지된
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, 미국, 92093
- 모병
- UC San Diego Moores Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 858-822-5354
- 이메일: cancercto@ucsd.edu
-
수석 연구원:
- Andrew M. Lowy
-
Loma Linda, California, 미국, 92357
- 정지된
- Veterans Affairs Loma Linda Healthcare System
-
Los Angeles, California, 미국, 90033
- 정지된
- USC / Norris Comprehensive Cancer Center
-
San Diego, California, 미국, 92103
- 정지된
- UC San Diego Medical Center - Hillcrest
-
-
Delaware
-
Newark, Delaware, 미국, 19718
- 정지된
- Christiana Care Health System-Christiana Hospital
-
Newark, Delaware, 미국, 19713
- 정지된
- Helen F Graham Cancer Center
-
Newark, Delaware, 미국, 19713
- 정지된
- Medical Oncology Hematology Consultants PA
-
Wilmington, Delaware, 미국, 19801
- 정지된
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Ruskin, Florida, 미국, 33570
- 정지된
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, 미국, 33612
- 모병
- Moffitt Cancer Center - McKinley Campus
-
연락하다:
- Site Public Contact
- 전화번호: 800-679-0775
- 이메일: ClinicalTrials@moffitt.org
-
수석 연구원:
- Andrew J. Sinnamon
-
Tampa, Florida, 미국, 33607
- 정지된
- Moffitt Cancer Center-International Plaza
-
Tampa, Florida, 미국, 33612
- 정지된
- Moffitt Cancer Center
-
Wesley Chapel, Florida, 미국, 33544
- 정지된
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta, Georgia, 미국, 30342
- 정지된
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, 미국, 30308
- 정지된
- Emory University Hospital Midtown
-
Atlanta, Georgia, 미국, 30322
- 정지된
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, 미국, 30303
- 정지된
- Grady Health System
-
Johns Creek, Georgia, 미국, 30097
- 정지된
- Emory Johns Creek Hospital
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Northwestern University
-
연락하다:
- Site Public Contact
- 전화번호: 312-695-1301
- 이메일: cancer@northwestern.edu
-
수석 연구원:
- Akhil Chawla
-
Chicago, Illinois, 미국, 60612
- 모병
- University of Illinois
-
수석 연구원:
- Aslam Ejaz
-
연락하다:
- Site Public Contact
- 전화번호: 312-355-3046
-
Geneva, Illinois, 미국, 60134
- 정지된
- Northwestern Medicine Cancer Center Delnor
-
Oak Brook, Illinois, 미국, 60523
- 정지된
- Northwestern Medicine Oak Brook
-
Orland Park, Illinois, 미국, 60462
- 정지된
- Northwestern Medicine Orland Park
-
Warrenville, Illinois, 미국, 60555
- 정지된
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 정지된
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 모병
- University of Kentucky/Markey Cancer Center
-
수석 연구원:
- Michael J. Cavnar
-
연락하다:
- Site Public Contact
- 전화번호: 859-257-3379
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- 정지된
- University Medical Center New Orleans
-
-
Maryland
-
Elkton, Maryland, 미국, 21921
- 정지된
- Christiana Care - Union Hospital
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 정지된
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, 미국, 49017
- 정지된
- Bronson Battle Creek
-
Grand Rapids, Michigan, 미국, 49503
- 정지된
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, 미국, 49503
- 정지된
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grand Rapids, Michigan, 미국, 49503
- 정지된
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Muskegon, Michigan, 미국, 49444
- 정지된
- Trinity Health Muskegon Hospital
-
Niles, Michigan, 미국, 49120
- 정지된
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, 미국, 49444
- 정지된
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, 미국, 49677
- 정지된
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, 미국, 49085
- 정지된
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, 미국, 49085
- 정지된
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Wyoming, Michigan, 미국, 49519
- 정지된
- University of Michigan Health - West
-
-
Minnesota
-
Aitkin, Minnesota, 미국, 56431
- 정지된
- Riverwood Healthcare Center
-
Baxter, Minnesota, 미국, 56425
- 정지된
- Essentia Health - Baxter Clinic
-
Brainerd, Minnesota, 미국, 56401
- 정지된
- Essentia Health Saint Joseph's Medical Center
-
Crosslake, Minnesota, 미국, 56442
- 정지된
- Essentia Health - Saint Joseph's Crosslake Clinic
-
Deer River, Minnesota, 미국, 56636
- 정지된
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, 미국, 56501
- 정지된
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, 미국, 55805
- 정지된
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, 미국, 55805
- 정지된
- Miller-Dwan Hospital
-
Duluth, Minnesota, 미국, 55805
- 정지된
- Essentia Health Cancer Center
-
Ely, Minnesota, 미국, 55731
- 정지된
- Essentia Health - Ely Clinic
-
Fosston, Minnesota, 미국, 56542
- 정지된
- Essentia Health - Fosston
-
Hibbing, Minnesota, 미국, 55746
- 정지된
- Essentia Health Hibbing Clinic
-
International Falls, Minnesota, 미국, 56649
- 정지된
- Essentia Health - International Falls Clinic
-
Moose Lake, Minnesota, 미국, 55767
- 정지된
- Essentia Health - Moose Lake Clinic
-
Park Rapids, Minnesota, 미국, 56470
- 정지된
- Essentia Health - Park Rapids
-
Pequot Lakes, Minnesota, 미국, 56472
- 정지된
- Essentia Health - Saint Joseph's Pequot Lakes Clinic
-
Pine River, Minnesota, 미국, 56474
- 정지된
- Essentia Health - Saint Joseph's Pine River Clinic
-
Sandstone, Minnesota, 미국, 55072
- 정지된
- Essentia Health Sandstone
-
Staples, Minnesota, 미국, 56479
- 정지된
- Essentia Health - Saint Joseph's Staples Clinic
-
Virginia, Minnesota, 미국, 55792
- 정지된
- Essentia Health Virginia Clinic
-
-
Missouri
-
Farmington, Missouri, 미국, 63640
- 모병
- Parkland Health Center - Farmington
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
Sainte Genevieve, Missouri, 미국, 63670
- 모병
- Sainte Genevieve County Memorial Hospital
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
St Louis, Missouri, 미국, 63131
- 모병
- Missouri Baptist Medical Center
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
Sullivan, Missouri, 미국, 63080
- 모병
- Missouri Baptist Sullivan Hospital
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
Sunset Hills, Missouri, 미국, 63127
- 모병
- BJC Outpatient Center at Sunset Hills
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68198
- 정지된
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, 미국, 89502
- 정지된
- Renown Regional Medical Center
-
-
New Jersey
-
Livingston, New Jersey, 미국, 07039
- 정지된
- Saint Barnabas Medical Center
-
New Brunswick, New Jersey, 미국, 08903
- 정지된
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- 정지된
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, 미국, 14642
- 정지된
- University of Rochester
-
Syracuse, New York, 미국, 13210
- 정지된
- State University of New York Upstate Medical University
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28203
- 정지된
- Carolinas Medical Center/Levine Cancer Institute
-
Concord, North Carolina, 미국, 28025
- 정지된
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58103
- 정지된
- Essentia Health Cancer Center-South University Clinic
-
Fargo, North Dakota, 미국, 58122
- 정지된
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, 미국, 58122
- 정지된
- Sanford Broadway Medical Center
-
Jamestown, North Dakota, 미국, 58401
- 정지된
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- 정지된
- University of Cincinnati Cancer Center-UC Medical Center
-
Columbus, Ohio, 미국, 43210
- 정지된
- Ohio State University Comprehensive Cancer Center
-
West Chester, Ohio, 미국, 45069
- 정지된
- University of Cincinnati Cancer Center-West Chester
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18104
- 모병
- Saint Luke's Cancer Center - Allentown
-
연락하다:
- Site Public Contact
- 전화번호: 610-776-4714
-
수석 연구원:
- Darius C. Desai
-
Bethlehem, Pennsylvania, 미국, 18015
- 모병
- Saint Luke's University Hospital-Bethlehem Campus
-
연락하다:
- Site Public Contact
- 전화번호: 484-503-4151
-
수석 연구원:
- Darius C. Desai
-
Chadds Ford, Pennsylvania, 미국, 19317
- 정지된
- Christiana Care Health System-Concord Health Center
-
Easton, Pennsylvania, 미국, 18045
- 모병
- Saint Luke's Hospital-Anderson Campus
-
연락하다:
- Site Public Contact
- 전화번호: 888-823-5923
- 이메일: ctsucontact@westat.com
-
수석 연구원:
- Darius C. Desai
-
Quakertown, Pennsylvania, 미국, 18951
- 모병
- Saint Luke's Hospital - Upper Bucks Campus
-
연락하다:
- Site Public Contact
- 전화번호: 610-776-4714
-
수석 연구원:
- Darius C. Desai
-
Stroudsburg, Pennsylvania, 미국, 18360
- 모병
- Saint Luke's Hospital - Monroe Campus
-
연락하다:
- Site Public Contact
- 전화번호: 888-823-5923
- 이메일: ctsucontact@westat.com
-
수석 연구원:
- Darius C. Desai
-
Wilkes-Barre, Pennsylvania, 미국, 18711
- 정지된
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57104
- 정지된
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls, South Dakota, 미국, 57117-5134
- 정지된
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37920
- 정지된
- University of Tennessee - Knoxville
-
Memphis, Tennessee, 미국, 38120
- 정지된
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Vermont
-
Burlington, Vermont, 미국, 05405
- 정지된
- University of Vermont and State Agricultural College
-
Burlington, Vermont, 미국, 05401
- 정지된
- University of Vermont Medical Center
-
-
Virginia
-
Richmond, Virginia, 미국, 23235
- 모병
- VCU Massey Cancer Center at Stony Point
-
연락하다:
- Site Public Contact
- 이메일: ctoclinops@vcu.edu
-
수석 연구원:
- Leopoldo J. Fernandez
-
Richmond, Virginia, 미국, 23298
- 모병
- VCU Massey Comprehensive Cancer Center
-
수석 연구원:
- Leopoldo J. Fernandez
-
연락하다:
- Site Public Contact
- 전화번호: 804-628-6430
- 이메일: CTOclinops@vcu.edu
-
Roanoke, Virginia, 미국, 24033
- 정지된
- Carilion Roanoke Memorial Hospital
-
Winchester, Virginia, 미국, 22601
- 정지된
- Valley Health / Winchester Medical Center
-
-
Washington
-
Seattle, Washington, 미국, 98195
- 정지된
- University of Washington Medical Center - Montlake
-
Seattle, Washington, 미국, 98109
- 정지된
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Ashland, Wisconsin, 미국, 54806
- 정지된
- Northwest Wisconsin Cancer Center
-
Ashland, Wisconsin, 미국, 54806
- 정지된
- Duluth Clinic Ashland
-
Hayward, Wisconsin, 미국, 54843
- 정지된
- Essentia Health-Hayward Clinic
-
Hayward, Wisconsin, 미국, 54843
- 정지된
- Tamarack Health Hayward Medical Center
-
Marshfield, Wisconsin, 미국, 54449
- 모병
- Marshfield Medical Center-Marshfield
-
연락하다:
- Site Public Contact
- 전화번호: 800-782-8581
- 이메일: oncology.clinical.trials@marshfieldresearch.org
-
수석 연구원:
- Jessica A. Wernberg
-
Mukwonago, Wisconsin, 미국, 53149
- 정지된
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, 미국, 53066
- 정지된
- ProHealth Oconomowoc Memorial Hospital
-
Spooner, Wisconsin, 미국, 54801
- 정지된
- Essentia Health-Spooner Clinic
-
Superior, Wisconsin, 미국, 54880
- 정지된
- Essentia Health Saint Mary's Hospital - Superior
-
Waukesha, Wisconsin, 미국, 53188
- 정지된
- ProHealth Waukesha Memorial Hospital
-
Waukesha, Wisconsin, 미국, 53188
- 정지된
- UW Cancer Center at ProHealth Care
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
-
Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
-
Participants must not have a known history of a prior diagnosis of malabsorption syndrome
-
Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
-
Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization
-
Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
-
Participants must be ≥ 18 years old
-
Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
-
Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization
-
Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:
- Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
- Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
- Bromocriptine: Dose adjustments may be considered to account for absorption changes
- Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
- CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy
- NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation
-
Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
-
Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)
-
Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking
-
Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study
-
NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
-
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm I (lanreotide, distal pancreatectomy)
Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
다른 이름들:
Undergo distal pancreatectomy Given SC
다른 이름들:
|
|
위약 비교기: Arm II (saline placebo, distal pancreatectomy)
Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
다른 이름들:
Undergo distal pancreatectomy Given SC
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of postoperative pancreatic fistula (POPF)
기간: Up to 60 days after distal pancreatectomy
|
POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of biochemical leak (BL)
기간: Up to 60 days after distal pancreatectomy
|
BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Number of post-operation hospital days
기간: From the time of surgery up to 60 days after distal pancreatectomy
|
Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor. |
From the time of surgery up to 60 days after distal pancreatectomy
|
|
Change in overall quality of life (QOL)
기간: At baseline and at 14 and 60 days after surgery
|
Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and at 14 and 60 days after surgery
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Changes in pancreatic specific QOL
기간: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Change in health-related QOL
기간: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Delayed gastric emptying (DGE)
기간: Up to 60 days after distal pancreatectomy
|
DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
기간: Up to 60 days after distal pancreatectomy
|
PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Time to initiation of adjuvant chemotherapy
기간: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test. |
From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
|
Incidence of nausea and vomiting
기간: Up to 60 days after distal pancreatectomy
|
Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test. |
Up to 60 days after distal pancreatectomy
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Jonathan G Sham, SWOG Cancer Research Network
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- S2408
- UG1CA189974 (미국 NIH 보조금/계약)
- NCI-2024-08361 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- SWOG-S2408 (기타 식별자: DCP)
- S2408 (기타 식별자: SWOG)
- S2408 (기타 식별자: CTEP)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .